Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

Fangxin Hong, PhD, Andrew M. Evens, DO, MSc, Paul J Novotny, M.S., Thomas M. Habermann, MD, Ranjana H Advani, MD, Randy D. Gascoyne, MD, Thomas E. Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Amylou C. Dueck, PhD, Brad S Kahl, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 4157.

https://doi.org/10.1182/blood-2018-99-117249

Published: 2018

Journal Articles

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

Lucia Baratto, MD, Opeyemi Jegede, PhD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Ranjana Advani, MD, Randy D. Gascoyne, MD, Lale Kostakoglu, MD, Thomas E. Witzig, MD, Erik A. Ranheim, MD PhD, Brad S Kahl, MD, Andrew Quon, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2018-99-113247

Published: 2018

Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD

Blood (2017) 130 (Supplement 1): 482.

https://doi.org/10.1182/blood.V130.Suppl_1.482.482

Published: 2017

Journal Articles

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Lode J. Swinnen, Hailun Li, MS, Andrew Quon, MD, Randy D. Gascoyne, MD, Erik A. Ranheim, MD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 687.

https://doi.org/10.1182/blood.V120.21.687.687

Published: 2012

Journal Articles

Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).

Eunice Y. Tsai, MD, Alan Taur, MD, Leandro Espinosa, MD, Andrew Quon, MD, Sarah E. Dick, MD, Steve Chow, MD, Ranjana Advani, MD, Roger A. Warnke, MD, Sabine Kohler, MD, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2004) 104 (11): 3127.

https://doi.org/10.1182/blood.V104.11.3127.3127

Published: 2004

NARROW

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).

Email alerts

ASH Publications

American Society of Hematology

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only